Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder

Owen, Randall, Sikich, Linmarie, Marcus, Ronald N., Corey-Lisle, Patricia, Manos, George, McQuade, Robert D., Carson, William H., Findling, Robert L. · 2009 · Pediatrics

Abstract

OBJECTIVE: The objective of this study was to evaluate short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder who were manifesting behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these. METHODS: This 8-week, double-blind, randomized, placebo-controlled, parallel-group study was conducted of children and adolescents (aged 6–17 years) with autistic disorder. Patients were randomly assigned (1:1) to flexibly dosed aripiprazole (target dosage: 5, 10, or 15 mg/day) or placebo. Efficacy outcome measures included the Aberrant Behavior Checklist irritability subscale and the Clinical Global Impression–Improvement score (CGI-I). Safety and tolerability were also assessed. RESULTS: Ninety-eight patients were randomly assigned to receive placebo (n = 51) or aripiprazole (n = 47). Mean improvement in Aberrant Behavior Checklist irritability subscale score was significantly greater with aripiprazole than with placebo from week 1 through week 8. Aripiprazole demonstrated significantly greater global improvements than placebo, as assessed by the mean CGI-I score from week 1 through week 8; however, clinically significant residual symptoms may still persist for some patients. Discontinuation rates as a result of adverse events (AEs) were 10.6% for aripiprazole and 5.9% for placebo. Extrapyramidal symptom-related AE rates were 14.9% for aripiprazole and 8.0% for placebo. No serious AEs were reported. Mean weight gain was 2.0 kg on aripiprazole and 0.8 kg on placebo at week 8. CONCLUSIONS: Aripiprazole was efficacious in children and adolescents with irritability associated with autistic disorder and was generally safe and well tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1542/peds.2008-3782

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 22 references

Cited by

See all 642

Metadata

Authors
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L.
Affiliations
  • Bristol-Myers Squibb (United States) (US)
  • University of North Carolina at Chapel Hill (US)
  • Bristol-Myers Squibb, Wallingford, Connecticut
  • Otsuka (United States) (US)
  • University Hospitals Cleveland Medical Center (US)
Venue
Pediatrics
Published
2009-12-01
Volume
124
Issue
6
Pages
1533-1540
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W2160438215
Cited by
613
References
22
Citations by year
2026: 20 · 2025: 24 · 2024: 34 · 2023: 25 · 2022: 30 · 2021: 53 · 2020: 43 · 2019: 30 · 2018: 38 · 2017: 42 · 2016: 43 · 2015: 34 · 2014: 36 · 2013: 40 · 2012: 50
FWCI
19.52
Type
journal article
Language
en
Open access
closed
Locations
  • PEDIATRICS (publishedVersion)
  • PubMed (publishedVersion)
Funders
Otsuka Pharmaceutical
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Keywords
aripiprazole, irritability, autistic disorder, autism spectrum disorder, children and adolescents, tantrums, aggression, self-harm, Aberrant Behavior Checklist, extrapyramidal symptoms, weight gain, antipsychotic efficacy and safety
MeSH terms
Aripiprazole, Adolescent, Autistic Disorder, Child, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Irritable Mood, Male, Personality Assessment, Piperazines, Antipsychotic Agents, Quinolones, Weight Gain, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder. https://app.cochat.ai/papers/10.1542/peds.2008-3782
The paper
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009). Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder. Pediatrics. https://doi.org/10.1542/peds.2008-3782

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.